Brief: FDA Approves Bayer's Kerendia For Kidney Disease Linked To Type 1 Diabetes

Bayer AG

17/09/2026 07:39

Sept 17 (Reuters) - BAYER AG BAYGn.DE:
BAYER’S KERENDIA® (FINERENONE) RECEIVES FDA APPROVAL AS THE FIRST NEW TREATMENT IN 30 YEARS FOR ADULTS WITH CHRONIC KIDNEY DISEASE (CKD) AND TYPE 1 DIABETES
KERENDIA APPROVED TO REDUCE CARDIOVASCULAR DEATH, HEART FAILURE HOSPITALIZATION IN HF LVEF ≥40%
FDA APPROVES KERENDIA AS FIRST NEW CKD TREATMENT FOR T1D IN 30 YEARS
KERENDIA APPROVAL SUPPORTED BY PHASE III FINE-ONE TRIAL DATA
KERENDIA REDUCES UACR BY 28% VERSUS PLACEBO AT MONTH 6
KERENDIA APPROVED TO REDUCE RISK OF EGRF DECLINE, KIDNEY DISEASE, CARDIOVASCULAR DEATH IN CKD WITH T2D
Source text: ID:nBw4FMkZSa
Further company coverage: [BAYGn.DE]

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))